Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients

被引:25
|
作者
Karabon, L. [1 ,2 ]
Partyka, A. [1 ]
Ciszak, L. [1 ]
Pawlak-Adamska, E. [1 ]
Tomkiewicz, A. [1 ]
Bojarska-Junak, A. [3 ]
Rolinski, J. [3 ]
Wolowiec, D. [4 ]
Wrobel, T. [4 ]
Frydecka, I. [1 ]
Kosmaczewska, A. [1 ]
机构
[1] Polish Acad Sci, Hirszfeld Inst Immunol & Expt Therapy, Dept Expt Therapy, Wroclaw, Poland
[2] Wroclaw Med Univ, Dept & Clin Urol & Oncol Urol, Wroclaw, Poland
[3] Med Univ Lublin, Dept Clin Immunol & Immunotherapy, Lublin, Poland
[4] Wroclaw Med Univ, Dept & Clin Haematol Blood Neoplasms & Bone Marro, Wroclaw, Poland
关键词
CD8(+) T-CELLS; B-LYMPHOCYTE; INFECTIOUS COMPLICATIONS; MEDIATES INHIBITION; CYCLE REGULATORS; CD152; CTLA-4; ATTENUATOR; RECEPTOR; CANCER; PROLIFERATION;
D O I
10.1155/2020/6545921
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Chronic lymphocytic leukemia (CLL) is characterized by the peripheral accumulation of neoplastic B cells and is frequently complicated by the systemic immunosuppression associated with an impairment in B and T lymphocyte activation. We hypothesized that the expression of immune checkpoint suppressors B and T lymphocyte attenuator (BTLA) and cytotoxic T lymphocyte antigen (CTLA-4) is disturbed in both lymphocyte subpopulations in CLL. The expression of CTLA-4 and BTLA mRNA was determined by real-time PCR, while CTLA-4 protein expression (surface or intracellular) was estimated in BTLA+ lymphocytes by flow cytometry. In CLL patients, we observed a higher gene transcript level of BTLA and CTLA-4 than in healthy individuals in both freshly isolated and PMA stimulated B and T cells. Remarkably, lower amounts of both inhibitory proteins were found in peripheral blood (PB) CLL B cells, whereas normal BTLA and elevated CTLA-4 were found in T cells. Consistently, there was a prevalence of CTLA-4+ cells within circulating BTLA+ T cells cells of patients confronting PB healthy cells. After in vitro stimulation, the only change found in CLL patients was a decrease in BTLA expression in B and T lymphocytes. In contrast, healthy lymphocytes responded more vigorously as regards the BTLA and CTLA expression with substantially higher frequency of CD69+ cells under the stimulating condition compared to corresponding cells from the CLL group. Our results indicate that CLL development is associated with the affected expression of BTLA and CTLA-4 checkpoint receptors in PB and its impaired expression might be associated with lowering of the threshold for B cell activation and proliferation, while upregulated CTLA-4 expression in CLL peripheral BTLA+ T cells may contribute to suppressed T cell effector functions. This hypothesis needs to be validated in future studies, which would allow us to explain how the increased or decreased expression of these molecules affects the cell function.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Immune defects in patients with chronic lymphocytic leukemia
    Farhad Ravandi
    Susan O’Brien
    Cancer Immunology, Immunotherapy, 2006, 55 : 197 - 209
  • [32] Immune defects in patients with chronic lymphocytic leukemia
    Ravandi, F
    O'Brien, S
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (02) : 197 - 209
  • [33] Case Series: Immune Checkpoint Inhibitor Therapy for Patients with Skin Tumors and chronic lymphocytic Leukemia
    Kleemann, J.
    Kaufmann, R.
    Meissner, M.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 45 - 45
  • [34] Regulation of chronic lymphocytic leukemia cell proliferation by CTLA4.
    Mittal, Amit K.
    Rohlfsen, Rae A.
    Joshi, Avadhut D.
    Hegde, Ganapati V.
    Bociek, R. Gregory
    Joshi, Shantararn S.
    BLOOD, 2007, 110 (11) : 346A - 346A
  • [35] Role of CTLA4 in the Proliferation and Survival of Chronic Lymphocytic Leukemia
    Mittal, Amit K.
    Chaturvedi, Nagendra K.
    Rohlfsen, Rae A.
    Gupta, Payal
    Joshi, Avadhut D.
    Hegde, Ganapati V.
    Bociek, R. Gregory
    Joshi, Shantaram S.
    PLOS ONE, 2013, 8 (08):
  • [36] Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia
    Cass, S. H.
    Tobin, J. W. D.
    Seo, Y. D.
    Gener-Ricos, G.
    Keung, E. Z.
    Burton, E. M.
    Davies, M. A.
    Mcquade, J. L.
    Lazar, A. J.
    Mason, R.
    Millward, M.
    Sandhu, S.
    Khoo, C.
    Warburton, L.
    Guerra, V.
    Haydon, A.
    Dearden, H.
    Menzies, A. M.
    Carlino, M. S.
    Smith, J. L.
    Mollee, P.
    Burgess, M.
    Mapp, S.
    Keane, C.
    Atkinson, V.
    Parikh, S. A.
    Markovic, S. N.
    Ding, W.
    Call, T. G.
    Hampel, P. J.
    Long, G., V
    Wargo, J. A.
    Ferrajoli, A.
    ANNALS OF ONCOLOGY, 2023, 34 (09) : 796 - 805
  • [37] The CTLA-4 gene polymorphisms are associated with CTLA-4 protein expression levels in multiple sclerosis patients and with susceptibility to disease
    Karabon, Lidia
    Kosmaczewska, Agata
    Bilinska, Malgorzata
    Pawlak, Edyta
    Ciszak, Lidia
    Jedynak, Anna
    Jonkisz, Anna
    Noga, Leszek
    Pokryszko-Dragan, Anna
    Koszewicz, Magdalena
    Frydecka, Irena
    IMMUNOLOGY, 2009, 128 (01) : e787 - e796
  • [38] The Immune Checkpoints CTLA-4 and LAG-3 Expression is Up-Regulated in Acute Myeloid Leukemia
    Radwan, Sara
    Elleboudy, Nooran
    Nabih, Nermeen
    Kamal, Amany
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S198 - S198
  • [39] CTLA-4 expression in T cells of patients with atopic dermatitis
    Choi, SY
    Sohn, MH
    Kwon, BC
    Kim, KE
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2005, 16 (05) : 422 - 427
  • [40] Study of CTLA-4 gene expression in patients with IDDM.
    Cavallo, MG
    Leytze, G
    Buzzetti, R
    Nistico, L
    Linsley, P
    Pozzilli, P
    DIABETES, 1997, 46 : 1319 - 1319